Trial Profile

A Phase 2a study of NKTR-358 in Alopecia-areata, an autoimmune indication

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 18 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rezpegaldesleukin (Primary)
Indications Alopecia areata
Focus Therapeutic Use

Most Recent Events

13 Sep 2023 According to a Nektar Therapeutics media release, the company will present the trial designs for Phase 2a study starting in early 2024 in alopecia areata at its investor and analyst event today.
03 May 2022 New trial record
25 Apr 2022 According to a Nektar Therapeutics media release, this trial is planned to start in 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com